HLX11 Matches Reference Pertuzumab in Neoadjuvant HER2-Positive Breast Cancer
A phase 3 equivalence trial found that the pertuzumab biosimilar HLX11 performed comparably with reference pertuzumab in the neoadjuvant treatment of HER2-positive, hormone receptor-negative early-stage or locally advanced breast cancer. The study used a randomized, double-blind design and paired both arms with trastuzumab and docetaxel, reflecting the standard biologic backbone used to drive tumor downstaging before surgery. The central clinical question was narrow and important: can a biosimilar deliver the same depth of tumor eradication without changing safety, pharmacokinetics, or immune behavior?
The answer, in this trial, was yes.
Equivalent Pathologic Response Across 908 Randomized Patients
A total of 908 patients entered the study, with 454 assigned to the HLX11 arm and 454 to the European Union-sourced pertuzumab arm. The primary endpoint was blinded independent central review-assessed total pathological complete response tpCR, a stringent measure in neoadjuvant breast oncology because it captures the disappearance of invasive disease in the resected specimen. In HER2-positive, hormone receptor-negative disease, a high tpCR rate carries immediate clinical relevance: it marks the ability of the regimen to extinguish chemosensitive, biologically aggressive tumor clones before surgery.
BICR-assessed tpCR reached 46.3% in the HLX11 arm and 45.8% in the reference arm. The absolute difference was small, and the trial met its equivalence criteria. The relative risk of tpCR was 1.01, with a 90% confidence interval of 0.90 to 1.14, while the relative difference was 0.47% with a 95% confidence interval from -5.99% to 6.92%. Those intervals sat within the prespecified bounds for equivalence, indicating that the biosimilar neither underperformed nor overshot the reference product in a clinically meaningful way.
The practical implication is direct: on the measure that matters most in this preoperative setting, HLX11 tracked closely with the originator drug.
Neoadjuvant Biology Supports the Observed Response Pattern
Pertuzumab and trastuzumab target complementary regions of the HER2 pathway, while docetaxel adds cytotoxic pressure during a window when rapidly proliferating tumor cells remain vulnerable. In hormone receptor-negative HER2-positive disease, this combination often produces a pronounced preoperative response because the tumor is heavily dependent on HER2 signaling and less buffered by endocrine escape routes. A biosimilar must preserve not just molecular similarity, but the downstream clinical behavior that follows receptor blockade and chemotherapy synergy. The trial data showed that HLX11 preserved that pattern.
No clinically meaningful differences emerged in other efficacy endpoints. The report does not need embellishment here: the neoadjuvant efficacy signal stayed aligned across both arms, which is exactly the kind of consistency regulators and treating oncologists look for when evaluating a biosimilar intended to substitute for a reference monoclonal antibody.
Safety, Pharmacokinetics, and Immunogenicity Stayed Aligned
Beyond response, the study examined whether any hidden divergence appeared in tolerability or biologic handling. It did not. Safety outcomes, pharmacokinetic profiles, and immunogenicity remained similar between HLX11 and reference pertuzumab. In a biosimilar program, those domains matter because a product can match tumor response yet still fail in practice if exposure varies, if anti-drug antibodies emerge differently, or if adverse events cluster in one treatment arm.
The absence of clinically meaningful differences suggests that HLX11 behaved like the reference antibody in circulation and at the bedside. For clinicians, that reduces concern about switching patients to a biosimilar version of pertuzumab in a setting where treatment intensity is already high and where preoperative timing leaves little room for dosing inconsistency.
Adjuvant Switching Did Not Change the Safety Profile
The study also extended into the postoperative phase. Patients who had received EU-pertuzumab were re-randomized to receive adjuvant HLX11 or EU-pertuzumab plus trastuzumab, while patients in the HLX11 arm received adjuvant HLX11 plus trastuzumab. This design provided a useful test of interchangeability in a continuation phase, when therapy often must be sustained after surgery to maintain suppression of residual microscopic disease.
Switching from EU-pertuzumab to HLX11 in the adjuvant phase produced no notable differences in safety, pharmacokinetics, or immunogenicity. For day-to-day oncology practice, this is one of the most consequential observations in the trial. A switch that preserves exposure and tolerability lowers the barrier to biosimilar adoption, especially in systems where formulary decisions, access, or procurement policies may change between the neoadjuvant and adjuvant phases of care.
Why the tpCR Endpoint Matters in HER2-Positive Disease
Pathological complete response is not a surrogate chosen for convenience. In HER2-positive breast cancer, especially when hormone receptor-negative, tpCR often reflects substantial disease sensitivity to dual HER2 blockade plus chemotherapy. While it does not replace long-term recurrence and survival endpoints, it gives an early readout of whether the drug combination is adequately disrupting the signaling circuitry that drives tumor growth and survival. Equivalent tpCR between HLX11 and the reference product therefore carries more weight than a simple similarity in laboratory assay results.
The trial outcome supports a mechanistic conclusion: the biosimilar preserved the biologic effect required to induce deep preoperative tumor regression. In a disease subtype where pathologic clearance can influence surgical and postoperative planning, that is a meaningful clinical result.
What This Trial Establishes for Practice
The data support HLX11 as a neoadjuvant pertuzumab biosimilar with equivalent efficacy to reference pertuzumab when combined with trastuzumab and docetaxel in early-stage or locally advanced HER2-positive, hormone receptor-negative breast cancer. The similarity extended beyond the main efficacy endpoint to safety, pharmacokinetics, and immunogenicity, and it held during adjuvant switching as well. For oncologists, the key message is not theoretical equivalence but operational confidence: the biosimilar reproduced the clinical performance expected from pertuzumab in a preoperative dual-HER2 blockade regimen.
Two limitations remain evident from the abstract-level data alone. Long-term recurrence outcomes are not presented here, and the clinical durability of the tpCR signal cannot be inferred from this summary alone. The trial does, however, provide a strong head-to-head equivalence dataset at the point where neoadjuvant treatment decisions are actually made: before surgery, under close monitoring, and in a disease subtype where response depth carries immediate therapeutic meaning.